J J Chang1, M Kim-Tenser2, B A Emanuel2, G M Jones1,3, K Chapple1, A Alikhani4, N Sanossian2, W J Mack5, G Tsivgoulis1,6, A V Alexandrov1, T Pourmotabbed7. 1. Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA. 2. Department of Neurology, Keck School of Medicine/University of Southern California, Los Angeles, CA, USA. 3. Department of Clinical Pharmacy and Neurosurgery, University of Tennessee Health Science Center, Memphis, TN, USA. 4. Department of Radiology, University of Tennessee Health Science Center, Memphis, TN, USA. 5. Department of Neurosurgery, Keck School of Medicine/University of Southern California, Los Angeles, CA, USA. 6. Second Department of Neurology, 'Attikon University Hospital', National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. 7. Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, USA.
Abstract
BACKGROUND AND PURPOSE:Intracerebral hemorrhage (ICH) is a devastating cerebrovascular disorder with high morbidity and mortality. Minocycline is a matrix metalloproteinase-9 (MMP-9) inhibitor that may attenuate secondary mechanisms of injury in ICH. The feasibility and safety of minocycline in ICH patients were evaluated in a pilot, double-blinded, placebo-controlled randomized clinical trial. METHODS:Patients with acute onset (<12 h from symptom onset) ICH and small initial hematoma volume (<30 ml) were randomized to high-dose (10 mg/kg) intravenous minocycline or placebo. The outcome events included adverse events, change in serial National Institutes of Health Stroke Scale score assessments, hematoma volume and MMP-9 measurements, 3-month functional outcome (modified Rankin score) and mortality. RESULTS: A total of 20 patients were randomized to minocycline (n = 10) or placebo (n = 10). The two groups did not differ in terms of baseline characteristics. No serious adverse events or complications were noted with minocycline infusion. The two groups did not differ in any of the clinical and radiological outcomes. Day 5 serum MMP-9 levels tended to be lower in the minocycline group (372 ± 216 ng/ml vs. 472 ± 235 ng/ml; P = 0.052). Multiple linear regression analysis showed that minocycline was associated with a 217.65 (95% confidence interval -425.21 to -10.10, P = 0.041) decrease in MMP-9 levels between days 1 and 5. CONCLUSIONS: High-dose intravenous minocycline can be safely administered to patients with ICH. Larger randomized clinical trials evaluating the efficacy of minocycline and MMP-9 inhibition in ICH patients are required.
RCT Entities:
BACKGROUND AND PURPOSE:Intracerebral hemorrhage (ICH) is a devastating cerebrovascular disorder with high morbidity and mortality. Minocycline is a matrix metalloproteinase-9 (MMP-9) inhibitor that may attenuate secondary mechanisms of injury in ICH. The feasibility and safety of minocycline in ICHpatients were evaluated in a pilot, double-blinded, placebo-controlled randomized clinical trial. METHODS:Patients with acute onset (<12 h from symptom onset) ICH and small initial hematoma volume (<30 ml) were randomized to high-dose (10 mg/kg) intravenous minocycline or placebo. The outcome events included adverse events, change in serial National Institutes of Health Stroke Scale score assessments, hematoma volume and MMP-9 measurements, 3-month functional outcome (modified Rankin score) and mortality. RESULTS: A total of 20 patients were randomized to minocycline (n = 10) or placebo (n = 10). The two groups did not differ in terms of baseline characteristics. No serious adverse events or complications were noted with minocycline infusion. The two groups did not differ in any of the clinical and radiological outcomes. Day 5 serum MMP-9 levels tended to be lower in the minocycline group (372 ± 216 ng/ml vs. 472 ± 235 ng/ml; P = 0.052). Multiple linear regression analysis showed that minocycline was associated with a 217.65 (95% confidence interval -425.21 to -10.10, P = 0.041) decrease in MMP-9 levels between days 1 and 5. CONCLUSIONS: High-dose intravenous minocycline can be safely administered to patients with ICH. Larger randomized clinical trials evaluating the efficacy of minocycline and MMP-9 inhibition in ICHpatients are required.
Authors: Konark Malhotra; Jason J Chang; Arjun Khunger; David Blacker; Jeffrey A Switzer; Nitin Goyal; Adrian V Hernandez; Vinay Pasupuleti; Andrei V Alexandrov; Georgios Tsivgoulis Journal: J Neurol Date: 2018-06-14 Impact factor: 4.849
Authors: Raina D Ramnath; Matthew J Butler; Georgina Newman; Sara Desideri; Amy Russell; Abigail C Lay; Chris R Neal; Yan Qiu; Sarah Fawaz; Karen L Onions; Monica Gamez; Michael Crompton; Chris Michie; Natalie Finch; Richard J Coward; Gavin I Welsh; Rebecca R Foster; Simon C Satchell Journal: Kidney Int Date: 2019-11-02 Impact factor: 10.612
Authors: Kathryn N Kearns; Natasha Ironside; Min S Park; Bradford B Worrall; Andrew M Southerland; Ching-Jen Chen; Dale Ding Journal: Neurocrit Care Date: 2021-08-02 Impact factor: 3.210